SMA Therapy: A Winding Path to Success – PTC Therapeutics

Learn how PTC Therapeutics developed our spinal muscular atrophy (SMA) therapy from beginning to end. Our founder and CEO Stuart Peltz, is joined by Nikolai Naryshkin, VP & Head of Group External Affairs and Alliance Management, Pannie Trifillis, VP & Head of Global Scientific Affairs, Matt Woll VP & Head of Chemistry and Arya Singh, Patient Advocate to take you through the development of this important therapy that will change the lives of people living with SMA.

Congratulations to the dedicated PTC team on this important milestone in our quest to end SMA!

Connect with PTC Therapeutics!





About PTC Therapeutics, Inc.

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.

#raredisease #patient #ptctherapeutics #pharma #science #medicine #SMA #spinalmuscularatrophy